Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copy-cats

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatment Ozempic, arguing the drugs are too complex for the pharmacies to make safely. Compounded anti-obesity drugs are sold at vastly lower prices than the branded versions...

No comments

Read more